News Breaks |
|
|
| February 6, 2013 |
| 07:08 EDT |  | VSTM | Verastem's VS5584 exhibits anti-tumor efficacy in published report
Verastem announced the publication of data for VS-5584, a selective inhibitor of the PI3K/mTOR pathway. The study details the biochemical properties and preclinical effects of this compound in multiple human tumor models. VS-5584 demonstrated potent and highly selective activity against class 1 PI3K enzymes and dual-inhibitory actions against mTORC1 and mTORC2. In addition to the biochemical effects, VS-5584 exhibited broad anti-tumor efficacy, including tumor regression, across multiple human tumor models in the published study. |
|
|
News For VSTM From The Last 14 Days Check below for free stories on VSTM the last two weeks. |
|
|
| May 22, 2013 |
| 10:14 EDT |  | VSTM | Verastem management to meet with Guggenheim
Meetings to be held on the West Coast May 23-24 hosted by Guggenheim. |
|
| 07:28 EDT | | VSTM | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link |
|
| May 21, 2013 |
| 07:44 EDT | | VSTM | Sachs Associates to host a forum
 Subscribe for More Information |
|
| May 14, 2013 |
| 07:04 EDT | | VSTM | Verastem appoints Jack Green as CFO
Subscribe for More Information |
|
| May 9, 2013 |
| 07:35 EDT |  | VSTM | Verastem reports Q1 EPS (44c), consensus (43c)
|
|
|
|
|
|
